Longevity protocols.
Protocol-grade ingestibles, topicals, and devices for clinic-led longevity practice.
Longevity is the category where the firm is most willing to refuse the work and most precise about which brands it engages. Decoded represents protocol-grade products — ingestibles, topicals, and devices — whose evidence pack would survive scrutiny in a clinical setting and whose channel posture matches the rest of the longevity practice (concierge clinic, longevity-focused hospital programme, qualified digital intake). GLP-1 adjacencies, NAD precursors, advanced photo-modulation, and continuous-monitoring devices are in scope when the brand's clinical and regulatory posture is coherent. Most are not.
The opportunity.
- Protocol-grade
- Evidence threshold
- Clinic-only
- Default channel
- Multi-format
- Ingestible / topical / device
Regulatory landscape.
Hybrid pathway: each SKU is classified into the operative regime per market — supplement, cosmetic, medical device, or therapeutic product. SG HSA's 2026 therapeutic-products updates (Journal F.3) and emerging GLP-1 adjacencies (Journal F.4) reshape this category fastest.
Channel landscape.
Concierge clinic networks, longevity-specialist hospitals, qualified telehealth intake where the regulator permits, and a controlled premium-pharmacy slice for the SKUs that genuinely belong there.
What Decoded looks for in a longevity brand.
- 01
Evidence pack a longevity practitioner would actually read before prescribing.
- 02
Clarity on which regulatory regime each SKU sits under, per market — no ambiguity.
- 03
Manufacturing posture matching the operative regime (GMP / GMP-equivalent / 21 CFR 820).
- 04
Brand willingness to accept clinic-led distribution without the firm relaxing into broader retail.
- 05
Pharmacovigilance and post-market reporting wired in from launch, not promised for later.